January 27, 2022
Life Sciences
  • Moderna Inc. said it began testing an omicron-specific version of its COVID-19 vaccine booster in a clinical trial among 600 adults who have received two or three doses of its existing shot. The announcement came one day after Pfizer Inc. launched its own similar trial. While it’s unclear an omicron-targeted shot will be needed, Moderna Chief Executive Stephane Bancel said the biotech is pursuing it because of “the long-term threat demonstrated by omicron’s immune escape.” (Articles here, here, and here)